The data demonstrated low rates of target lesion revascularisation (TLR) and side branch failure (3.6 and 1.2%, respectively), with no incidences of stent thromboses.
Tryton Medical president and CEO Greg Davis said that they were pleased that these results confirm positive outcomes seen in earlier studies, including excellent six-month clinical and angiographic results in their first-in-man study and good six-month clinical results from four different registries.
The company’s Tryton Side Branch Stent System is designed to offer a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation.
